Cellectis (CLLS) Consolidated Net Income (2015 - 2026)
Cellectis (CLLS) posted quarterly Consolidated Net Income of -$8.8 million for Q1 2026, down 471.42% year-over-year from $2.4 million in Q1 2025, and up 91.68% quarter-over-quarter from -$105.5 million in Q4 2025.
Analysis
Cellectis (CLLS) Consolidated Net Income (2015 - 2026) Analysis & Trends
Cellectis' Consolidated Net Income history runs 12 years deep, the most recent figure standing at -$8.8 million for Q1 2026.
- In Q1 2026, Consolidated Net Income fell 471.42% year-over-year to -$8.8 million; the TTM figure through Mar 2026 stood at -$76.3 million (down 144.88% YoY), while the FY2023 annual figure was $8.4 million, up 154.69% from the prior year.
- Consolidated Net Income for Q1 2026 stood at -$8.8 million, up from -$105.5 million in the prior quarter.
- The five-year high for Consolidated Net Income was $22.4 million in Q3 2025, with the low at -$105.5 million in Q4 2025.
- The 5-year median for Consolidated Net Income is -$2.9 million (2022), against an average of -$8.8 million.
- The sharpest annual moves came in 2023 and 2026: Consolidated Net Income jumped 3059.95% in 2023, then sank 471.42% in 2026.
- Cellectis' Consolidated Net Income stood at -$2.9 million in 2022, then jumped by 557.93% to $13.1 million in 2023, then sank by 414.52% to -$41.1 million in 2024, then tumbled by 156.49% to -$105.5 million in 2025, then soared by 91.68% to -$8.8 million in 2026.
- Business Quant data shows CLLS's Consolidated Net Income at -$8.8 million in Q1 2026, -$105.5 million in Q4 2025, and $22.4 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - | -15.75 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -15.75 Mn |
| Mar 31, 2026 | -8.78 Mn |
| Dec 31, 2025 | -3.42 Mn |
| Sep 30, 2025 | 22.41 Mn |
| Jun 30, 2025 | 15.65 Mn |
| Mar 31, 2025 | 2.37 Mn |
| Dec 31, 2024 | -37.78 Mn |
| Sep 30, 2024 | 2.86 Mn |
| Jun 30, 2024 | -25.31 Mn |
| Mar 31, 2024 | 11.39 Mn |
| Dec 31, 2023 | -118.06 Mn |
| Sep 30, 2023 | -546,000.00 |
| Jun 30, 2023 | 17.56 Mn |
| Mar 31, 2023 | -26.57 Mn |
| Dec 31, 2022 | -5.61 Mn |
| Sep 30, 2022 | -29.09 Mn |
| Jun 30, 2022 | -19.45 Mn |
| Mar 31, 2022 | -12.06 Mn |
| Dec 31, 2021 | -13.71 Mn |
| Sep 30, 2021 | -42.37 Mn |